On Demand Pharmaceuticals Demonstrates Point-of-Care Manufacturing Platform to HHS Officials
Key Insights
On Demand Pharmaceuticals (search) hosted senior HHS officials at its Maryland facility, showcasing its Pharmacy on Demand platform through a live virtual demonstration of real-time essential medicine formulation.
The visit highlights a multi-year collaboration between ODP, DoD, and HHS's ASPR to reshore America's pharmaceutical manufacturing infrastructure amid persistent drug shortages (search).
ODP's distributed manufacturing model addresses critical vulnerabilities, as over 90% of generic sterile injectable APIs (search) used in U.S. hospitals rely on foreign sources.
On Demand Pharmaceuticals (search) (ODP) hosted senior officials from the U.S. Department of Health and Human Services (search) (HHS) at its Centralized Production and Repackaging (CPR) facility in Rockville, Maryland, demonstrating breakthrough capabilities in domestic pharmaceutical manufacturing. The visit featured a live virtual demonstration of ODP's Pharmacy on Demand® (PoD) platform streaming from its Tupelo site at North Mississippi Medical Center (search), where attendees witnessed real-time formulation of essential medicines (search).
Strategic Partnership Addresses National Vulnerabilities
The demonstration marks a significant milestone in the multi-year collaboration between ODP, the Department of Defense (search) (DoD), and HHS's Administration for Strategic Preparedness and Response (search) (ASPR). This partnership focuses on reshoring America's pharmaceutical manufacturing infrastructure as the U.S. confronts persistent drug shortages (search) and supply chain disruptions stemming predominantly from quality and reliability issues of foreign manufacturers.
According to HHS data presented during the visit, over 90% of generic sterile injectable APIs (search) used in U.S. acute care hospitals rely on foreign sources, creating significant vulnerabilities in the nation's healthcare supply chain. ODP's distributed manufacturing model offers a resilient, scalable, and rapid-response solution to deliver vital medications when and where they are needed.
"At ODP, we have reimagined pharmaceutical manufacturing using the most advanced techniques to ensure quality and provide transparency," said Matt Pietras, Chief Executive Officer of On Demand Pharmaceuticals (search). "We are positioned to scale delivery of our nation's most essential medications, made in America."
Advanced Manufacturing Technology
ODP's modular PoD platform can produce sterile medications (search) at or near health systems, making it uniquely suited to address drug shortages (search), eliminate single points of failure caused by natural disasters, and address public health emergencies. The platform is powered by AI-driven process controls and integrates end-to-end production, from chemical synthesis to final formulation and packaging.
The CPR facility in Rockville serves as a key national resource for the domestic small-scale manufacturing of active pharmaceutical ingredients (search) (APIs), a sector long dominated by foreign suppliers. This facility represents a critical component in reducing America's dependence on overseas pharmaceutical production.
Nationwide Expansion Plans
Leveraging significant public and private funding, ODP is delivering on its mission to improve medication access, eliminate drug shortages (search), and establish a novel platform for on-demand production of therapeutics at or near the point of care. The company is expanding its formulary to include medicines most at risk of shortage and is beginning to build its nationwide network of distributed production nodes.
"Today's visit by HHS underscores our shared commitment to building a more transparent, secure and agile domestic pharmaceutical supply chain," Pietras added. "Through our Pharmacy on Demand platform combined with our API production and repackaging capabilities, ODP is delivering a first-of-its-kind solution to produce essential medicines (search) at or near the point of care."
The company's model directly supports the HHS-led initiative to "make the United States the most competitive nation in the world for the manufacture of safe and effective pharmaceutical products," focusing on securing the supply chain for the nation's most essential medications while improving patient access, enhancing national security, and reducing reliance on foreign supply chains.